Cargando…

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70

BACKGROUND: This ongoing follow-up study evaluated the persistence of efficacy and immune responses for 6 additional years in adults vaccinated with the glycoprotein E (gE)-based adjuvanted recombinant zoster vaccine (RZV) at age ≥50 years in 2 pivotal efficacy trials (ZOE-50 and ZOE-70). The presen...

Descripción completa

Detalles Bibliográficos
Autores principales: Boutry, Céline, Hastie, Andrew, Diez-Domingo, Javier, Tinoco, Juan Carlos, Yu, Chong-Jen, Andrews, Charles, Beytout, Jean, Caso, Covadonga, Cheng, Huey-Shinn, Cheong, Hee Jin, Choo, Eun Ju, Curiac, Dan, Di Paolo, Emmanuel, Dionne, Marc, Eckermann, Tamara, Esen, Meral, Ferguson, Murdo, Ghesquiere, Wayne, Hwang, Shinn-Jang, Avelino-Silva, Thiago Junqueira, Kosina, Pavel, Liu, Chiu-Shong, Markkula, Jukka, Moeckesch, Beate, Murta de Oliveira, Cláudia, Park, Dae Won, Pauksens, Karlis, Pirrotta, Paola, Plassmann, Georg, Pretswell, Carol, Rombo, Lars, Salaun, Bruno, Sanmartin Berglund, Johan, Schenkenberger, Isabelle, Schwarz, Tino, Shi, Meng, Ukkonen, Benita, Zahaf, Toufik, Zerbini, Cristiano, Schuind, Anne, Cunningham, Anthony L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9049256/
https://www.ncbi.nlm.nih.gov/pubmed/34283213
http://dx.doi.org/10.1093/cid/ciab629